Loading
Bausch Health Companies Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 28 Nov 2025.
Bausch Health Companies Inc.: what insiders have been doing
Every trade that managers of Bausch Health Companies Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Laval, Canada. It was founded in 1960. Between 18 October 2025 and 18 October 2026, 30 insiders published 67 filings.
Both sides are active: 1 purchase worth €13.6M and 3 sales worth €328k, from 1 insider and 2 insiders respectively. On balance, insiders were net buyers of €13.2M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €13.6M, bought by Paulson & Co. Inc. and made public on 28 November 2025.
Compared with its exchange (5,458 companies, median 22 filings), a count of 67 filings is above the norm. Our records for Bausch Health Companies Inc. go back to 2016, with 8 purchases and 14 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 10.27 bn USD and net income at 157.0 m USD.
The latest purchase dates back some time: it was published 324 days ago, on 28 November 2025. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
305
Thresholds
n/a
Buy Volume
€316M
8 ops. · all time
Sell Volume
€2M
14 ops. · all time
Who traded when
BuySaleJohn Paulson4 buys
Mirza Dautbegovic2 sales
Aimee Lenar1 sale
Lee Frank D.1 sale
Paulson & Co. Inc.1 buy
Since the insiders bought
- -10.6%Entry US$7.05 · Close 16 Oct 2026 US$6.30
- -21.1%Entry US$8.34 · Close at T+365 US$6.58
- -68.2%Entry US$23.73 · Close at T+365 US$7.55
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Bausch Health Companies Inc. Hold (neutral), based on 5 analysts. Average price target: US$7.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,557 of 24,148 companies
63.0
score / 100
Value82
Quality44
FCF yld42%
Earn yld6.7%
EV/EBITDA7.3x
ROE·
Gross mgn71%
Net mgn1.5%
Debt/EBITDA6.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.30
Analyst consensus
5 analystsHold
US$6.50Target US$7.50(+19%)US$9.00
Income statement
RevenueUS$10.3B
Gross profitUS$7.3B71% margin
EBITDAUS$3.2B31% margin
Net incomeUS$157M-10.1% margin
Valuation
PER (forward)1.5x
Beta0.37
Balance sheet & cash
Market capUS$2.4B
Total debtUS$20.9B
Free Cash FlowUS$993M
Profitability & ownership
ROA6.6%
% insiders11.1%
% institutions65.1%
Last declaration on 2 October 2026
Declarations305 total
5,789 shares@ CA$5.830.0011% mcap50.2% of flowRights Restricted Share Units (RSUs)TSXSEDI:4784431
10,720 shares@ CA$5.830.0020% mcap50.1% of flowRights Restricted Share Units (RSUs)TSXSEDI:4784421
1,179 shares@ CA$5.830.0002% mcap50.2% of flowRights Restricted Share Units (RSUs)TSXSEDI:4784416
1,179 shares@ US$5.830.0003% mcap1.5% of flowCommon Shares, No Par ValueSEC:0000885590-26-000111:0
5,789 shares@ US$5.830.0015% mcap51.7% of flowCommon Shares, No Par ValueSEC:0000885590-26-000113:0
10,720 shares@ US$5.830.0029% mcap0.0% of flowCommon Shares, No Par ValueSEC:0000885590-26-000115:0
36,827 shares@ CA$7.030.0086% mcap47.6% of flowCommon SharesTSXSEDI:4767534
36,827 shares@ US$7.030.012% mcap47.4% of flowCommonSEC144:0001959173-26-006198
20,000 shares@ CA$7.000.0046% mcap51.8% of flowCommon SharesTSXSEDI:4758471
20,000 shares@ CA$6.500.0043% mcap48.2% of flowCommon SharesTSXSEDI:4758470
5,260 sharesCommon SharesTSXSEDI:4754278
10,282 shares@ CA$4.830.0017% mcap9.2% of flowRights Restricted Share Units (RSUs)TSXSEDI:4754271
23,395 sharesCommon SharesTSXSEDI:4754261
48,117 shares@ CA$4.890.0078% mcap43.3% of flowRights Restricted Share Units (RSUs)TSXSEDI:4754257
5,260 shares@ US$4.830.0012% mcap4.7% of flowCommon Shares, No Par ValueSEC:0000885590-26-000101:0
23,395 shares@ US$4.890.0053% mcap21.2% of flowCommon Shares, No Par ValueSEC:0000885590-26-000099:0
3,125 sharesCommon SharesTSXSEDI:4752929
Common SharesTSXSEDI:4752922
9,123 shares@ CA$4.750.0014% mcap100.0% of flowRights Restricted Share Units (RSUs)TSXSEDI:4752920
3,125 shares@ US$4.750.0007% mcap100.0% of flowCommon Shares, No Par ValueSEC:0000885590-26-000097:0
1,394 shares@ CA$4.930.0002% mcap100.0% of flowRights Restricted Share Units (RSUs)TSXSEDI:4744574
12,677 shares@ CA$4.930.0021% mcap100.0% of flowRights Restricted Share Units (RSUs)TSXSEDI:4744566
6,845 shares@ CA$4.930.0011% mcap100.0% of flowRights Restricted Share Units (RSUs)TSXSEDI:4744552
6,845 sharesCommon Shares, No Par ValueSEC:0000885590-26-000091:0
12,677 sharesCommon Shares, No Par ValueSEC:0000885590-26-000093:0
25 of 305 declarations
About Bausch Health Companies Inc.
Bausch Health Companies Inc. is a diversified healthcare company listed on the NYSE/NASDAQ in the United States (United States), with a business mix spanning pharmaceuticals, medical devices, aesthetics, and eye health through its controlling interest in Bausch + Lomb. The company’s global headquarters are in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. For equity investors, Bausch Health stands out as a specialized healthcare platform with a broad portfolio of established brands and a meaningful presence in niche therapeutic categories.
The company develops, manufactures, and markets products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, and international pharmaceuticals, and it also participates in eye health through Bausch + Lomb. Its portfolio includes branded prescription medicines, branded generics, and OTC products. Bausch Health says it sells directly or indirectly in more than 90 countries and regions, including the United States, Canada, Europe, the Middle East, Africa, Asia Pacific, and Latin America. That geographic spread gives the group a diversified revenue base, although performance remains influenced by execution in a handful of core franchises.
Read moreShow less
From a competitive standpoint, Bausch Health is not a mega-cap pharmaceutical company, but it has carved out defensible positions in selected specialty markets. In U.S. medical dermatology, its Ortho Dermatologics business is described by the company as one of the largest prescription dermatology companies in the world, supporting its relevance in specialty care. Bausch + Lomb adds a major ophthalmology and vision-care component, while the core Bausch Health portfolio provides exposure to chronic and specialty therapies that tend to be less commoditized than mass-market generics. This combination makes the company a hybrid between a specialty pharma operator and a broader healthcare asset platform.
Recent developments have been material. On February 18, 2026, Bausch Health reported full-year 2025 revenue of $10.27 billion and continued improvement in adjusted EBITDA, while also noting the acquisition of Shibo’s full-service aesthetics distribution business in China, which expands its footprint in aesthetic treatments. On April 29, 2026, management reaffirmed full-year 2026 guidance and highlighted continued investment in its pipeline, including larsucosterol for alcohol-associated hepatitis. The company also completed significant debt refinancing actions in 2025, an important factor for investors given Bausch Health’s historical leverage profile. Overall, the name remains a global healthcare company with a diversified product base, ongoing portfolio development, and a balance-sheet story that remains central to the investment case.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
